UCB Unveils Neupro Drug in U.S. Market
UCB has launched Neupro (Rotigotine Transdermal System) in US pharmacies for the treatment of Parkinson's disease (PD) and Restless Legs Syndrome (RLS).
Neupro received the US Food and Drug Administration approval on 3 April 2012.
UCB CEO Roch Doliveux said the availability of Neupro is an important step forward for US patients living with Parkinson's disease and Restless Legs Syndrome.
"UCB is dedicated to delivering innovative medicines like the Neupro® transdermal patch to people living with serious illnesses such as Parkinson's disease and Restless Legs Syndrome, by combining the latest science and technology with our researchers' insights on the holistic needs of patients," Doliveux added.
Baylor College of Medicine Parkinson's Disease Center and Movement Disorders director Joseph Jankovic said both the diseases are serious, neurological diseases.
"The often unpredictable, debilitating nature of these diseases can require consistent, sustained symptom control throughout the day and night," Jankovic added.
One million Americans are currently living with PD while RLS could affect around 23 million Americans.